Anti-Mouse IL-15 Antibody (AIO.3) 

Anti-Mouse IL-15 Antibody (AIO.3) is a rat-derived IgG2a λ type antibody inhibitor, targeting to mouse IL-15. Anti-Mouse IL-15 Antibody (AIO.3) can neutralize IL-15. Anti-Mouse IL-15 Antibody (AIO.3) can be used for the researches of cancer, infection and inflammation, such as hepatitis virus infection and esophagitis^{[1][2][3][4][5]}.

Rat IgG2a kappa

Rat IgG2a kappa, Isotype Control

Mouse

IL-15

The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Mouse IL-15 Antibody (AIO.3) (25 µg/mouse, i.p., daily from from day -1 to day 2 of the infection) shows anti-infection effect by neutralizing IL-15 in mouse hepatitis virus infected mice models^[1].
Anti-Mouse IL-15 Antibody (AIO.3) (4 mg/kg, i.v., twice a week) is effective in preserving coagulation factor VIII expression and has broad anti-inflammatory effects in adeno-associated viral (AAV)-transduced hemophilia A mice^[2].
Anti-Mouse IL-15 Antibody (AIO.3) (300 µg/mouse, i.p., 3 times a week) ameliorates podocyte injury and glomerulosclerosis in Adriamycin (HY-121309)-induced focal segmental glomerulosclerosis mice models^[3].
Anti-Mouse IL-15 Antibody (AIO.3) (100 µg, i.v., at days 0, 4, 7, 11, 14, 18) reduces esophageal eosinophilia in experimental eosinophilic esophagitis mice models^[4].
Anti-Mouse IL-15 Antibody (AIO.3) (1 mg/kg, i.p., daily from day 5 to 11) reduces therapeutic effect in response to anti-CD40 agonist in intravesical tumor mice models^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

16168  [NCBI]

P48346

in vivo IL-15 neutralization; in vitro IL-15 neutralization

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

150 kDa

Liquid

Colorless to light yellow

[Anti-Mouse IL-15 Antibody (AIO.3)]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Immobilized IL-15 Protein, Mouse (HEK293, Fc, HY-P78719) can bind Anti-Mouse IL-15 Antibody (AIO.3). The EC₅₀ for this effect is 62.13 ng/mL.

• [1]. Gil-Cruz C, et al. Fibroblastic reticular cells regulate intestinal inflammation via IL-15-mediated control of group 1 ILCs. Nat Immunol. 2016 Dec;17(12):1388-1396.  [Content Brief]

  [2]. Butterfield JSS, et al. IL-15 blockade and rapamycin rescue multifactorial loss of factor VIII from AAV-transduced hepatocytes in hemophilia A mice. Mol Ther. 2022 Dec 7;30(12):3552-3569.  [Content Brief]

  [3]. Li L, et al. Targeting tissue-resident memory CD8+ T cells in the kidney is a potential therapeutic strategy to ameliorate podocyte injury and glomerulosclerosis. Mol Ther. 2022 Aug 3;30(8):2746-2759.  [Content Brief]

  [4]. Vicari AP, et al. Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis. MAbs. 2017 Aug/Sep;9(6):927-944.  [Content Brief]

  [5]. Wong JL, et al. IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer. Proc Natl Acad Sci U S A. 2023 Aug 29;120(35):e2306782120.  [Content Brief]